FDA says Ozempic, Wegovy are not in short supply anymore, which could impact prices
The U.S. Food and Drug Administration said Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply. CBS News New York reporter Ali Bauman reports on whether the supply change could lead to consumers paying more.
New Scientist on MSN10d
Strongest evidence yet that Ozempic and Wegovy reduce alcohol intakeThe drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...
American demand for weight-loss drugs is supercharging Denmark’s economy and transforming a small Danish community into an ...
People using semaglutide for diabetes or weight loss have also reported experiencing a reduced desire for alcohol. A new ...
A new case study is the latest to suggest that GLP-1 therapy can tamp down people's unhealthy cravings of drugs like alcohol ...
Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback